Delpharm

Delpharm ranks among Europe's largest independent pharmaceutical manufacturers, operating a network of production sites across France, Germany, Belgium, the Netherlands, Italy, Finland, and India. The group works exclusively as a contract development and manufacturing organisation, meaning it produces finished dosage forms for pharmaceutical companies rather than marketing its own branded medicines.

The company's manufacturing capabilities span a broad range of solid oral forms, semi-solids, liquids, injectables, and inhalation products. Its sites hold regulatory approvals from the EMA, the FDA, and other major health authorities, enabling supply to markets across Europe, North America, and beyond. This multi-site, multi-authority footprint makes Delpharm a strategic partner for companies needing compliant, flexible capacity across different dosage technologies.

Contract pharmaceutical manufacturing at Delpharm encompasses both commercial-scale production and development services, covering formulation development, clinical trial supply, and technology transfer. The group serves originator companies, generics manufacturers, and biotech firms seeking outsourced capacity without committing to their own infrastructure.

Headquartered in France, Delpharm has grown substantially through acquisition, assembling a pan-European platform of specialist sites, each carrying distinct technology strengths. The group is privately held and has been backed by private equity, which has supported its consolidation strategy within the European CDMO sector.

Further information is available at delpharm.com.